Inclusion Criteria

Inclusion Criteria

Concurrent Medication:

Recommended:

- PCP prophylaxis.

Allowed:

- GM-CSF or G-CSF.

- Erythropoietin.

- Therapies (including antiretrovirals) available through expanded access or treatment
IND programs.

- Other non-experimental therapies available by prescription.

- Antihistamines other than those specifically excluded.

Patients must have:

- Evidence or diagnosis of HIV infection or a history of an AIDS-defining condition by
CDC criteria.

- CD4 count <= 100 cells/mm3 within 90 days prior to study entry.

- Two baseline blood sample cultures negative for MAC within 30 days of study entry.

- No suspected disseminated MAC disease, in the opinion of the clinician.

NOTE:

- Patients with elevated GGT and/or triglycerides are allowed.

NOTE:

- Patients may co-enroll on ACTG 081/981/181, ACTG 175, ACTG 204, ACTG 193, ACTG 241,
or other acceptable protocols.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

- Known or suspected tuberculous infection or other non-tuberculous mycobacterial
infection requiring chemotherapy or chemoprophylaxis (with the exception of isoniazid
prophylaxis alone).

NOTE:

- Patients may enroll who successfully completed tuberculosis (TB) treatment and have
been off anti-TB drugs for more than 6 months with no symptoms of mycobacterial
infection.

- Active TB.

- Known hypersensitivity to study drugs.

- Malabsorption as defined by persistent diarrhea with more than 8 stools per day for >
6 weeks.

Concurrent Medication:

Excluded:

- Frequent (more than once per month), repeated, or continuous treatment courses of
quinolones, erythromycin, spiramycin, azithromycin, clarithromycin, or clindamycin.

- Concomitant terfenadine or astemizole.

Prior Medication:

Excluded:

- Prophylaxis with azithromycin, clarithromycin, or rifabutin for more than 4 months.